

Freedom of Information Request

Ref: 25-271

6 May 2025

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some of the information you are requesting

I am writing to request information under the Freedom of Information Act 2000 in England and Wales and Freedom of Information Act 2002 (Scotland). I would like to request data on the treatment of patients with hormone therapies for prostate cancer at your Trust for the period January 1, 2023- December 31, 2024. Specifically, I am seeking the following information:

Request for Information

For each of the following hormone therapies used to treat prostate cancer, please provide the number of patients treated at your Trust between 01 January and 31 December (by years 2023 and 2024). For each therapy, broken down the data into the following categories:

1. Total Number of Patients Treated for ICD-10 C61 / M1-M1c (metastatic)

ABIRATERONE: 2023: 64 (60 had mets) 2024: 28 (27 had mets)

APALUTAMIDE: 2023: 19 (16 had mets) 2024: 46 (37 had mets)

ENZALUTAMIDE: 2023: 268 (242 had mets) 2024: 320 (299 had mets)

DAROLUTAMIDE & DOCETAXEL: 2023: 8 (8 had mets) 2024: 12 (12 had mets)

DAROLUTAMIDE: 2023: 21 (* had mets) 2024: 35 (10 had mets)

DOCETAXEL: 2023: 45 (36 had mets) 2024: 44 (32 had mets)

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts,

providers and Trusts may allow identification of patients and should not be published.

2. Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M1-M1c (metastatic)

ABIRATERONE: 2023: 18 (16 had mets) 2024: 18 (17 had mets)

APALUTAMIDE: 2023: 9 (8 had mets) 2024: 21 (21 had mets)

ENZALUTAMIDE: 2023: 89 (88 had mets) 2024: 98 (94 had mets)

DAROLUTAMIDE & DOCETAXEL: 2023: 8 (8 had mets) 2024: 8 (8 had mets)

DAROLUTAMIDE: 2023: 8 (* had mets) 2024: 15 (7 had mets)

DOCETAXEL: 2023: 28 (27 had mets) 2024: 32 (26 had mets)

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, providers and Trusts may allow identification of patients and should not be published.

3. Number of Patients for Whom Hormone Therapy Was Continued; ICD-10 C61 / M1-M1c (metastatic)

ABIRATERONE: 2023: 46 (44 had mets) 2024: 10 (10 had mets)

APALUTAMIDE: 2023: 10 (8 had mets) 2024: 19 (16 had mets)

ENZALUTAMIDE: 2023: 158 (154 had mets) 2024: 208 (205 had mets)

DAROLUTAMIDE & DOCETAXEL: 2023: 0 2024: * (* had mets)

DAROLUTAMIDE: 2023: 11 (* had mets) 2024: 11 (* had mets)

DOCETAXEL: 2023: 12 (9 had mets) 2024: 7 (6 had mets)

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, providers and Trusts may allow identification of patients and should not be published.

4. Number of patients for whom docetaxel was initiated for ICD-10 C61 / M1-M1c (localised & metastatic) – please see the response to question 2

The hormone therapies of interest are:

a) ADT alone

b) Abiraterone (Zytiga) in combination with any ADT

- c) Abiraterone (Zytiga) – no ADT
- d) Enzalutamide (Xtandi) in combination with any ADT
- e) Enzalutamide (Xtandi) – no ADT
- f) Apalutamide (Erleada) in combination with any ADT
- g) Darolutamide (Nubeqa) in combination with any ADT
- h) Darolutamide (Nubeqa) in combination with any ADT with docetaxel
- i) Docetaxel in combination with any ADT

Total number of patients in each year, for each therapy for whom:

- ☐ **Hormone therapy was initiated**
- ☐ **Hormone therapy was continued**
- ☐ **Docetaxel was initiated**

Please note that we can only report on androgen receptor pathway inhibitors (ARPIs), as androgen deprivation therapies (ADTs) are started and continued by GPs.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust